Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs f…
Biotechnology
US, Cranbury [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 20.85 | -38.24 | -48.32 | |
| Graham Fair Price | -3.67 | 8.39 | 8.71 | |
| PEG | 303.21 | -3.22 | 0.80 | |
| Price/Book | -0.30 | 5.66 | 5.68 | |
| Price/Cash Flow | 48.45 | -42.43 | -82.31 | |
| Prices/Earnings | 14.09 | -10.07 | -11.72 | |
| Price/Sales | inf | 0.00 | 271.27 | |
| Price/FCF | 48.45 | -42.43 | -82.31 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | inf | 0.00 | 0.50 | |
| Operating Margin | inf | 0.00 | -6.14 | |
| ROA | -17.94 | -0.12 | -0.11 | |
| ROE | -0.12 | -0.14 | -16.04 | |
| ROIC | -0.13 | -0.14 | -14.77 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.04 | < 0.005 | 546.88 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.03 | -0.06 | 96.98 | |
| EPS QOQ | 0.15 | -0.03 | -78.69 | |
| FCF QOQ | 0.45 | -0.73 | 62.99 | |
| Revenue QOQ | 0.00 | -1.00 | -100.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.05 | 0.06 | 14.74 | |
| Quick Ratio | 7.69 | 10.28 | 33.66 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 5.28 | 4.72 | -10.57 | |
| Cash | 4.00 | 3.53 | -11.69 | |
| Capex | -0.05 | -0.02 | 56.31 | |
| Free Cash Flow | -0.36 | -0.63 | -72.96 | |
| Revenue | 0.11 | 0.00 | inf | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad